The effect of Enzalutamide and Radium-233 chloride for castration-resistant prostate cancer patients with bone metastasis

The effect of Enzalutamide and Radium-233 chloride for castration-resistant prostate cancer patients with bone metastasis - The effect of Enzalutamide and Radium-223 chloride for CRPC patients with bone metastasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031347

Enrollment

Registered

2018-02-17

Start date

2018-02-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration-resistant prostate cancer patients with bone metastasis

Interventions

Administration of Radium-233 chloride Administration of Radium-233 chloride and Enzalutamide

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The case of castration-resistant prostate cancer patients with bone metastasis

Exclusion criteria

Exclusion criteria: The case of Distant metastasis other than bone metastasis or visceral metastasis

Design outcomes

Primary

Measure	Time frame
To elucidate the effect of Enzalutamide and Radium-223 chloride for CRPC patients with bone metastasis	—

Secondary

Measure	Time frame
Time to PSA failure, Time to SSE, Safty.	—

Countries

Japan

Contacts

Public ContactKiyoshi Takahara

Fujita Health University Hospital Department of Urology

takahara@fujita-hu.ac.jp0562-93-9257

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026